Demographics and baseline characteristics
| n (%) . | 50 mg qod (n = 6) . | 50 mg (n = 3) . | 100 mg (n = 4) . | 150 mg (n = 4) . | 200 mg (n = 4) . | 250 mg (n = 4) . | 300 mg (n = 16) . | Total (N = 41) . |
|---|---|---|---|---|---|---|---|---|
| Sex | ||||||||
| Female | 4 (66.7) | 0 | 1 (25.0) | 2 (50.0) | 2 (50.0) | 3 (75.0) | 6 (37.5) | 18 (43.9) |
| Male | 2 (33.3) | 3 (100.0) | 3 (75.0) | 2 (50.0) | 2 (50.0) | 1 (25.0) | 10 (62.5) | 23 (56.1) |
| Race | ||||||||
| Asian | 2 (33.3) | 0 | 0 | 0 | 0 | 0 | 2 (12.5) | 4 (9.8) |
| Black or African American | 0 | 0 | 0 | 2 (50.0) | 0 | 0 | 1 (6.3) | 3 (7.3) |
| White | 4 (66.7) | 3 (100.0) | 3 (75.0) | 2 (50.0) | 3 (75.0) | 4 (100.0) | 12 (75.0) | 31 (75.6) |
| Age | ||||||||
| Median (range), y | 70.5 (64-87) | 73 (63-82) | 62 (57-89) | 55 (52-74) | 66.5 (34-82) | 67.5 (59-78) | 71 (41-78) | 69 (34-89) |
| ≥65 years | 5 (83.3) | 2 (66.7) | 1 (25.0) | 1 (25.0) | 2 (50.0) | 3 (75.0) | 11 (68.8) | 25 (61.0) |
| ECOG performance status | ||||||||
| 0 | 1 (16.7) | 1 (33.3) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 4 (25.0) | 9 (22.0) | |
| 1 | 5 (83.3) | 2 (66.7) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 12 (75.0) | 31 (75.6) |
| Previous lines of therapy | ||||||||
| 1 | 1 (16.7) | 2 (66.7) | 3 (75.0) | 0 | 1 (25.0) | 0 | 4 (25.0) | 11 (26.8) |
| 2 | 1 (16.7) | 1 (33.3) | 0 | 0 | 2 (50.0) | 2 (50.0) | 5 (31.3) | 11 (26.8) |
| ≥3 | 4 (66.7) | 0 | 1 (25.0) | 4 (100.0) | 1 (25.0) | 2 (50.0) | 7 (43.8) | 19 (46.3) |
| Median (range) | 3 (1-7) | 1 (1-2) | 1 (1-5) | 3 (3-4) | 2 (1-4) | 2.5 (2-5) | 2 (1-5) | 2 (1-7) |
| Type of previous therapies | ||||||||
| Venetoclax | 6 (100.0) | 3 (100.0) | 4 (100.0) | 3 (75.0) | 4 (100.0) | 3 (75.0) | 16 (100.0) | 39 (95.1) |
| HMA | 5 (83.3) | 3 (100.0) | 4 (100.0) | 4 (100.0) | 4 (100.0) | 4 (100.0) | 15 (93.7) | 39 (95.1) |
| Allogeneic SCT | 2 (33.3) | 0 | 1 (25.0) | 1 (25.0) | 1 (25.0) | 0 | 3 (18.7)) | 8 (19.5) |
| Anthracyclines | 4 (66.7) | 1 (33.3) | 2 (50.0) | 4 (100.0) | 3 (75.0) | 2 (50.0) | 6 (14.6) | 22 (53.7) |
| Mutation-targeted agent | 0 | 0 | 0 | 1 (25.0) | 0 | 2 (50.0) | 3 (18.7) | 6 (14.6) |
| n (%) . | 50 mg qod (n = 6) . | 50 mg (n = 3) . | 100 mg (n = 4) . | 150 mg (n = 4) . | 200 mg (n = 4) . | 250 mg (n = 4) . | 300 mg (n = 16) . | Total (N = 41) . |
|---|---|---|---|---|---|---|---|---|
| Sex | ||||||||
| Female | 4 (66.7) | 0 | 1 (25.0) | 2 (50.0) | 2 (50.0) | 3 (75.0) | 6 (37.5) | 18 (43.9) |
| Male | 2 (33.3) | 3 (100.0) | 3 (75.0) | 2 (50.0) | 2 (50.0) | 1 (25.0) | 10 (62.5) | 23 (56.1) |
| Race | ||||||||
| Asian | 2 (33.3) | 0 | 0 | 0 | 0 | 0 | 2 (12.5) | 4 (9.8) |
| Black or African American | 0 | 0 | 0 | 2 (50.0) | 0 | 0 | 1 (6.3) | 3 (7.3) |
| White | 4 (66.7) | 3 (100.0) | 3 (75.0) | 2 (50.0) | 3 (75.0) | 4 (100.0) | 12 (75.0) | 31 (75.6) |
| Age | ||||||||
| Median (range), y | 70.5 (64-87) | 73 (63-82) | 62 (57-89) | 55 (52-74) | 66.5 (34-82) | 67.5 (59-78) | 71 (41-78) | 69 (34-89) |
| ≥65 years | 5 (83.3) | 2 (66.7) | 1 (25.0) | 1 (25.0) | 2 (50.0) | 3 (75.0) | 11 (68.8) | 25 (61.0) |
| ECOG performance status | ||||||||
| 0 | 1 (16.7) | 1 (33.3) | 1 (25.0) | 1 (25.0) | 1 (25.0) | 4 (25.0) | 9 (22.0) | |
| 1 | 5 (83.3) | 2 (66.7) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 3 (75.0) | 12 (75.0) | 31 (75.6) |
| Previous lines of therapy | ||||||||
| 1 | 1 (16.7) | 2 (66.7) | 3 (75.0) | 0 | 1 (25.0) | 0 | 4 (25.0) | 11 (26.8) |
| 2 | 1 (16.7) | 1 (33.3) | 0 | 0 | 2 (50.0) | 2 (50.0) | 5 (31.3) | 11 (26.8) |
| ≥3 | 4 (66.7) | 0 | 1 (25.0) | 4 (100.0) | 1 (25.0) | 2 (50.0) | 7 (43.8) | 19 (46.3) |
| Median (range) | 3 (1-7) | 1 (1-2) | 1 (1-5) | 3 (3-4) | 2 (1-4) | 2.5 (2-5) | 2 (1-5) | 2 (1-7) |
| Type of previous therapies | ||||||||
| Venetoclax | 6 (100.0) | 3 (100.0) | 4 (100.0) | 3 (75.0) | 4 (100.0) | 3 (75.0) | 16 (100.0) | 39 (95.1) |
| HMA | 5 (83.3) | 3 (100.0) | 4 (100.0) | 4 (100.0) | 4 (100.0) | 4 (100.0) | 15 (93.7) | 39 (95.1) |
| Allogeneic SCT | 2 (33.3) | 0 | 1 (25.0) | 1 (25.0) | 1 (25.0) | 0 | 3 (18.7)) | 8 (19.5) |
| Anthracyclines | 4 (66.7) | 1 (33.3) | 2 (50.0) | 4 (100.0) | 3 (75.0) | 2 (50.0) | 6 (14.6) | 22 (53.7) |
| Mutation-targeted agent | 0 | 0 | 0 | 1 (25.0) | 0 | 2 (50.0) | 3 (18.7) | 6 (14.6) |
ECOG, Eastern Cooperative Oncology Group; qod, every other day dosing.